Theriva Biologics, Inc. (TOVX)

Theriva Biologics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	12.12	11.61	23.18	41.79	67.33	6.23
Cash & Short-Term Investments	12.12	11.61	23.18	41.79	67.33	6.23
Cash Growth	-26.96%	-49.91%	-44.53%	-37.93%	981.18%	-58.61%
Other Receivables	1.88	3.32	1.94	0.23	-	0.47
Receivables	1.88	3.32	1.94	0.23	-	0.47
Prepaid Expenses	0.7	0.98	1.17	1.21	1.08	0.77
Other Current Assets	0.05	0.37	1.12	2.29	0.46	0.47
Total Current Assets	14.74	16.28	27.4	45.52	68.86	7.93
Property, Plant & Equipment	1.34	1.54	2.18	1.54	1.48	0.45
Goodwill	-	-	5.7	5.53	-	-
Long-Term Deferred Charges	19.62	17.36	19.76	19.15	-	-
Other Long-Term Assets	0.13	0.17	0.18	0.12	0.02	0.02
Total Assets	35.83	35.35	55.22	71.86	70.37	8.41
Accounts Payable	0.61	0.86	0.77	0.92	0.52	0.89
Accrued Expenses	9.78	4.51	4.51	2.9	2.91	1.79
Current Portion of Long-Term Debt	0.06	0.06	0.06	0.06	-	-
Current Portion of Leases	0.61	0.54	0.49	0.22	0.12	0.29
Other Current Liabilities	1.34	1.61	0.91	2.97	-	-
Total Current Liabilities	12.39	7.59	6.74	7.06	3.55	2.97
Long-Term Debt	1.64	0.09	0.16	0.22	-	-
Long-Term Leases	0.58	0.87	1.44	1.19	1.4	0.19
Long-Term Deferred Tax Liabilities	-	-	-	1.62	-	-
Other Long-Term Liabilities	10.59	7.74	7.18	7.21	-	-
Total Liabilities	25.21	16.29	15.52	17.3	4.96	3.15
Common Stock	0.01	0	0	0.02	0.01	0.03
Additional Paid-In Capital	362.46	355.5	346.54	343.75	336.68	240.82
Retained Earnings	-352.35	-334.97	-309.32	-290.97	-271.28	-248.09
Treasury Stock	-0.29	-0.29	-0.29	-0.29	-	-
Comprehensive Income & Other	0.79	-1.18	0.03	-0.68	-	-
Total Common Equity	10.62	19.07	36.96	51.83	65.41	-7.24
Minority Interest	-	-	-	-	-	-2.77
Shareholders' Equity	10.62	19.07	39.7	54.56	65.41	5.26
Total Liabilities & Equity	35.83	35.35	55.22	71.86	70.37	8.41
Total Debt	2.89	1.57	2.15	1.68	1.53	0.47
Net Cash (Debt)	9.23	10.04	21.02	40.11	65.8	5.75
Net Cash Growth	-37.49%	-52.22%	-47.58%	-39.05%	1043.52%	-59.83%
Net Cash Per Share	2.74	7.45	32.63	65.41	134.97	75.67
Filing Date Shares Outstanding	9.6	2.78	0.69	0.6	0.63	0.52
Total Common Shares Outstanding	9.06	2.78	0.69	0.6	0.53	0.12
Working Capital	2.35	8.7	20.67	38.46	65.3	4.97
Book Value Per Share	1.17	6.85	53.89	85.67	123.84	-61.91
Tangible Book Value	10.62	19.07	31.26	46.31	65.41	-7.24
Tangible Book Value Per Share	1.17	6.85	45.58	76.54	123.84	-61.91
Machinery	0.74	0.71	0.9	0.9	0.83	0.81
Leasehold Improvements	0.09	0.09	0.09	0.09	0.09	0.44

Updated Aug 11, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q